Australia markets open in 2 hours 6 minutes

Castle Biosciences, Inc. (CSTL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
35.67-0.60 (-1.67%)
As of 03:53PM EST. Market open.

Castle Biosciences, Inc.

505 South Friendswood Drive
Suite 401
Friendswood, TX 77546
United States
866 788 9007
https://castlebiosciences.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees311

Key executives

NameTitlePayExercisedYear born
Mr. Derek J. MaetzoldFounder, CEO, Pres & Director1.02MN/A1962
Mr. Frank StokesChief Financial Officer656.26kN/A1970
Mr. Bernhard E. SpiessConsultant528.35kN/A1961
Ms. Kristen M. Oelschlager R.N., RNChief Operating OfficerN/AN/A1968
Camilla ZuckeroExec. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Alice Bahner IzzoVP of MarketingN/AN/AN/A
Mr. Toby W. JuvenalChief Commercial OfficerN/AN/A1961
Dr. Robert W. Cook Ph.D.Sr. VP of R&DN/AN/A1972
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Corporate governance

Castle Biosciences, Inc.’s ISS governance QualityScore as of 26 September 2021 is 10. The pillar scores are Audit: 4; Board: 8; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.